Nothing said here yet.
to join the conversation.
The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders.
Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform.
Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting ...
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical results demonstrating ...
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion ...
Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty revenue growth Ended first quarter 2026 with approximately ...
FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, ...
Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers Strategic focus on investigator-initiated exploratory studies and institutional collaborations Continued progress toward ...